Navigation Links
Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.  

The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The protein activity is what damages muscle cells and leads to progressive muscle weakness and atrophy in FSHD patients.

The genetic and disease mechanisms of FSHD were discovered by an international team of scientists led by Stephen Tapscott, M.D., Ph.D., a member of the Fred Hutch Human Biology Division, in a series of studies published between 2010 and early 2012. Tapscott will lead the Fred Hutch work in the GSK collaboration.

The team's discoveries also have implications for developing cancer immunotherapies because researchers also discovered that DUX4 regulates cancer/testis antigens. Cancer/testis antigens are encoded by genes that are normally expressed only in the human germ line but are also abnormally expressed in various tumor types, including melanoma and carcinomas of the bladder, lung and liver. This knowledge will give researchers a way to manipulate the expression of cancer/testis antigens, potentially opening the opportunity to use these antigens in a cancer vaccine.

The partnership with GSK is a first of its kind for Fred Hutch, which is also the first U.S.-based institution to sign on with GSK's "Discovery Partnership with Academia" (DPAc) program. GSK launched the program last year to combine the insight and creativity of the academic world with GSK's drug-discovery expertise to turn innovative research into medicines that benefit patients.

GSK currently has DPAc collaborations in place with Cambridge University and the University of Dundee in the U.K.

Unlike traditional licensing agreements in which the licensee is given full control to develop a discovery, the collaboration will involve GSK and Fred Hutch scientists working together to develop, test and hopefully bring to market a clinical treatment.

"GSK has huge expertise in developing agents against protein activity, so our opportunity to work with them is fantastic," Tapscott said.

"At GSK we believe that combining our drug-discovery expertise with the in-depth disease knowledge of specialist academic groups can seed innovation and help speed up the discovery and development of new medicines," said Pearl Huang, global head of DPAc. "We're excited to be expanding our academic program in North America and are looking forward to working closely with scientists like Dr. Tapscott, whose deep understanding of disease biology will complement our own work in this field."

FSHD affects about one in 20,000 individuals and usually begins in late adolescence. The effects start around the facial and upper-extremity muscles and eventually progress to muscles in the lower extremity. People with more severe FSHD become wheelchair bound and their life spans are often shortened.

In an era of flat federal research funding, this collaboration signals an increasing interest on the part of Fred Hutch to develop partnerships that further its lifesaving and innovative research.

"We're looking for more creative academic-industry partnerships like this one between Fred Hutch and GSK," said Ulrich Mueller, vice president of industry relations and technology transfer at Fred Hutch.

Tapscott's research on FSHD, which provides the scientific basis for the collaboration with GSK, was funded by Friends of FSH Research, the National Institute of Neurological Disorders and Stroke, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Financial terms of the Fred Hutch-GSK partnership were not disclosed.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit or follow Fred Hutch on Facebook, Twitter or YouTube.

Dean Forbes
206-605-0311 cell
206-667-2896 desk

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
2. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
3. Quebec Clinic Launches Canadian Use of Elektas Agility Beam-Shaping Innovation for Radiation Therapy of Cancer
4. German Cancer Research Center Selects Contur ELN from Accelrys
5. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
6. Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
7. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
8. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
9. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
10. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
11. The Oncology Nurse Community To Host Live Webinar On Cancer Pain Management
Post Your Comments:
(Date:10/9/2015)... Calif. , Oct. 9, 2015 AcelRx Pharmaceuticals, ... will be made at the annual European Society of Emergency ... to October 14 th , 2015 at the Lingotto Congress ... EuSEM is the largest meeting of emergency medicine practitioners in ... countries represented. Data from the previously announced phase ...
(Date:10/9/2015)... 2015 Ansun BioPharma announced a presentation at ... ) regarding the compassionate use of DAS181 under an ... who was co-infected with influenza and parainfluenza (Abstract # ... O 2 requirement was reduced and the patient,s ... go off the respirator on day 5. Between day ...
(Date:10/9/2015)... -- Der " JCA-Mauvernay Award   2015 ... und Dr.   Junko Takita    --> Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr. ...    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, wird am ...
Breaking Medicine Technology:
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:
(Date:10/10/2015)... , ... October 10, 2015 , ... "I have to walk with crutches for the ... 6.1 million Americans who live this way. Anything that would give me more independence and ... without having to use my hands." , He developed the STRAP IN to enable an ...
(Date:10/10/2015)... ... 10, 2015 , ... Story Chaser is a one-of-a-kind app that ... classics and inspiring stories and as words drop down and users tap the corresponding ... aesthetic and can be interacted with, making it a more engaging game. Users can ...
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation ... Graduate Medical Education J. Michael Finley, DO, as the recipient of the 2015 ... his impact on graduate medical education opportunities for osteopathic residents, and his dedication ...
(Date:10/9/2015)... , ... October 09, 2015 , ... With the FCPX ... pop grades to footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. This pack comes with 60 vibrant CUBE LUT files. ...
Breaking Medicine News(10 mins):
... mind,s reward centers are less enthused, brain scans find , ... you see your paycheck may have a lot to do ... by researchers at the University of Bonn in Germany. , ... male volunteers divided into pairs. Each pair, in adjoining brain ...
... with a devastating brain injury that has wiped out ... to understand other peoples feelings and intentions, according to ... the Baycrest Centre for Aging and the Brain, and ... The study, published in the Nov. 23, 2007 issue ...
... midday sleepiness, experts say, , , THURSDAY, Nov. 22 (HealthDay ... the Thanksgiving feast aren,t rare, and experts say a ... holiday. , It may have to do with the ... -- a chemical known to promote sleepiness, said Donna ...
... on the future treatment of breast cancer have been identified ... published in the online open access journal Breast Cancer Research ... priorities. , A team led by Professor Mitch Dowsett, ... based in London and Surrey, together with colleagues from the ...
... Health Company,(Amex: FHC ) today announced that it ... Analyst Conference on Wednesday, November 28,2007 at the Princeton ... 5th and,6th). The Company,s CEO, O.B. Parrish, and its ... a.m. Eastern Time (EST)., A "live" webcast of ...
... more ozone, and more strain on hearts, researchers say ... and high ozone levels work together to boost death ... They believe that global warming -- which brings more ... number of people who die of cardiovascular events. , ...
Cached Medicine News:
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
... II Hybrid External Fixation System incorporating ... in hybrid fixation. It incorporates features ... is designed to offer speed of ... Hoffmann® snap-fit technology. , ,Using the ...
... to add individual components for individual indications. ... indications. Made of an innovative composite plastic ... only much lighter. This means it's easier ... comfortable for the patient. ,Come pre-assembled, packaged ...
The Hybrid Fixator consists of Three basic components: rings, wires, clamps. Final fracture reduction can be easily performed after frame assembly....
Medicine Products: